FrancophonIA/ELRC3.0 huggingface dataset:
English: No dose adjustment is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.
Danish: Dosisjustering er ikke nødvendig til patienter med nedsat nyrefunktion eller til hæmodialysepatienter med ESRD.
English: The terminal half-life of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 11 hours.
Danish: Aprepitants terminale halveringstid efter en intravenøs dosis på 150 mg fosaprepitant var ca. 11 timer.
English: Interaction studies with fosaprepitant 150 mg and chemotherapeutic medicinal products have not been conducted; however, based on studies with oral aprepitant and docetaxel and vinorelbine, IVEMEND 150 mg is not expected to have a clinically relevant interaction with intravenously administered docetaxel and vinorelbine.
Danish: Der er ikke udført interaktionsstudier med fosaprepitant 150 mg og kemoterapeutika; på baggrund af studier med oral aprepitant og docetaxel og vinorelbin forventes IVEMEND 150 mg dog ikke at have klinisk relevant interaktion med intravenøst administreret docetaxel og vinorelbin.
English: * For paediatric patients 12 years and older, administer IVEMEND intravenously over 30 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.
Danish: * Hos pædiatriske patienter i alderen 12 år og derover administreres IVEMEND intravenøst over 30 minutter, og infusionen skal være afsluttet cirka 30 minutter før kemoterapi.
English: For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Danish: Opbevaringsforhold for lægemidlet efter rekonstitution og fortynding, se pkt.
English: Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Danish: Samtidig administration af pimozid, terfenadin, astemizol eller cisaprid (se pkt.
English: The potential for effects of fosaprepitant and aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies.
Danish: Muligheden for fosaprepitants og aprepitants indvirkning på fertiliteten er ikke tilstrækkeligt belyst, idet der i dyreforsøg ikke kunne opnås eksponeringsniveauer, der lå over den terapeutiske eksponering hos mennesker.
English: Interactions with other medicinal products following administration of intravenous fosaprepitant are likely to occur with active substances that interact with oral aprepitant.
Danish: Der må forventes de samme interaktioner med andre lægemidler efter administration af intravenøs fosaprepitant som ved oral aprepitant.
English: Fosaprepitant 150 mg, given as a single dose, is a weak inhibitor of CYP3A4.
Danish: Fosaprepitant 150 mg, givet som enkeltdosis, er en svag hæmmer af CYP3A4.
English: Disodium edetate, polysorbate 80, lactose anhydrous, NaOH and/or HCl diluted (for pH adjustment).
Danish: Dinatriumedetat, polysorbat 80, lactose, vandfri, fortyndet NaOH og/eller HCl, (til justering af pH).
English: Paediatric Patients Receiving 3-Day Fosaprepitant Regimen The efficacy of the 3-day fosaprepitant regimen in paediatric patients was based on that demonstrated in paediatric patients receiving the 3-day oral aprepitant regimen.
Danish: Pædiatriske patienter, der fik 3-dages fosaprepitantregime Virkningen af det 3-dages fosaprepitantregime hos pædiatriske patienter blev baseret på den virkning, som blev påvist hos pædiatriske patienter, der fik det 3-dages orale aprepitantregime.
English: 115 mg intravenously
Danish: 115 mg intravenøst
English: In an active-controlled clinical study in adult patients receiving HEC, safety was evaluated for 1,143 patients receiving the 1-day regimen of IVEMEND 150 mg compared to 1,169 patients receiving the 3-day regimen of aprepitant.
Danish: I et aktivt kontrolleret studie med voksne, der fik højemetogen kemoterapi, blev sikkerheden vurderet hos 1.143 patienter, der fik et 1-dages behandlingsregime med fosaprepitant 150 mg, og sammenlignet med 1.169 patienter, der fik et 3-dages behandlingsregime med aprepitant.
English: IVEMEND can affect other medicines both during and after treatment with IVEMEND.
Danish: Brug af anden medicin sammen med IVEMEND IVEMEND kan påvirke virkningen af andre lægemidler både under og efter behandling med IVEMEND.
English: For short term treatment, these findings are considered unlikely to be clinically relevant.
Danish: Disse fund anses sandsynligvis ikke for at være kliniske relevante ved kortidsbehandling.
English: Parenteral medicines should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.
Danish: Parenterale lægemidler skal undersøges visuelt for partikler og misfarvning før administration, hvis det er muligt.
English: See the Summary of Product Characteristics (SmPC) for EMEND capsules or EMEND for oral suspension for appropriate dosing instructions.
Danish: Se produktresuméet for EMEND kapsler eller EMEND pulver til oral suspension for hensigtsmæssige doseringsanvisninger.
English: CARTON 150 mg
Danish: KARTON 150 mg
English: Tabulated list of adverse reactions - fosaprepitant The following are adverse reactions reported in adult patients receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above.
Danish: Følgende er bivirkninger, som er rapporteret hos voksne patienter, der fik fosaprepitant i kliniske studier eller efter markedsføring, og som ikke er rapporteret for aprepitant som beskrevet ovenfor.
English: The potential for reproductive toxicities of fosaprepitant and aprepitant have not been fully characterised, since exposure levels above the therapeutic exposure in humans could not be attained in animal studies.
Danish: Fosaprepitants og aprepitants mulige reproduktionstoksicitet er ikke tilstrækkeligt belyst, idet der i dyreforsøg ikke kunne opnås eksponeringsniveauer, der lå over den terapeutiske eksponering hos mennesker.
English: There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment.
Danish: Der foreligger begrænsede data for patienter med moderat nedsat leverfunktion og ingen data for patienter med svært nedsat lever funktion.
English: For paediatric patients less than 12 years, administer IVEMEND intravenously over 60 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.
Danish: Hos pædiatriske patienter under 12 år administreres IVEMEND intravenøst over 60 minutter, og infusionen skal være afsluttet cirka 30 minutter før kemoterapi.
English: The geometric mean plasma clearance of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 73 ml/min.
Danish: Aprepitants gennemsnitlige geometriske plasmaclearance efter en intravenøs dosis på 150 mg fosaprepitant var ca. 73 ml/min.
English: Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Danish: Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com Ċipru
English: No dose adjustment is necessary for the elderly (see section 5.2).
Danish: Dosisjustering er ikke nødvendig hos ældre patienter (se pkt.
English: Infusion site reactions (ISRs) have been reported with the use of IVEMEND (see section 4.4).
Danish: Der er rapporteret reaktioner på infusionsstedet ved brug af IVEMEND (se pkt.
English: Additional adverse reactions were observed in adult patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Danish: Der blev observeret yderligere bivirkninger hos voksne, som blev behandlet med aprepitant mod postoperativ kvalme og opkastning (PONV) og med højere frekvens end for ondansetron: Øvre abdominalsmerter, abnorme tarmlyde, obstipation*, dysartri, dyspnø, hypæstesi, søvnløshed, myosis, kvalme, sensorisk forstyrrelse, mavegener, subileus*, nedsat synsskarphed, hvæsende vejrtrækning.
English: Another or additional non-hormonal form of birth control should be used during treatment with IVEMEND and for up to 2 months after using IVEMEND, - cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants), - alfentanil, fentanyl (used to treat pain), - quinidine (used to treat an irregular heart beat), - irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer), - medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines), - warfarin, acenocoumarol (blood thinners; blood tests may be required), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections), - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - nefazodone (used to treat depression), - diltiazem (a medicine used to treat high blood pressure), - corticosteroids (such as dexamethasone), - anti-anxiety medicines (such as alprazolam), - tolbutamide (a medicine used to treat diabetes)
Danish: - Ciclosporin, tacrolimus, sirolimus, everolimus (medicin der hæmmer dannelsen af antistoffer) - Alfentanil, fentanyl (til behandling af smerter) - Quinidin (til behandling af uregelmæssig hjerterytme) - Irinotecan, etoposid, vinorelbin, ifosfamid (medicin til behandling af cancer) - Lægemidler der indeholder sekalealkaloidderivater såsom ergotamin og diergotamin (til behandling af migræne) - Warfarin, acenocoumarol (midler til blodfortynding; det kan måske være nødvendigt at tage blodprøver) - Rifampicin, clarithromycin, telithromycin (antibiotika til behandling af infektioner) - Phenytoin (til behandling af krampeanfald) - Carbamazepin (til behandling af depression eller epilepsi) - Midazolam, triazolam, phenobarbital (beroligende midler eller sovemidler) - Perikon (et naturlægemiddel til behandling af depression) - Proteasehæmmere (til behandling hiv-infektioner) - Ketoconazol undtagen shampoo (til behandling af Cushings syndrom - når kroppen producerer for meget kortisol) - Itraconazol, voriconazol, posaconazol (svampemidler) - Nefazodon (til behandling af depression) - Diltiazem (til behandling af forhøjet blodtryk) - Kortikosteroider (såsom dexamethason) - Angstdæmpende midler (såsom alprazolam) - Tolbutamid (medicin til behandling af diabetes (sukkersyge)).
English: After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (1 mg/ml).
Danish: Efter rekonstituering og fortynding indeholder 1 ml opløsning 1 mg fosaprepitant (1 mg/ml).
English: The reconstituted and diluted final solution is stable for 24 hours at 25C.
Danish: Den endelige rekonstituerede og fortyndede opløsning er stabil i 24 timer ved 25 ºC.
English: Assure that sodium chloride 9 mg/ml (0.9 %) solution for injection is added to the vial along the vial wall in order to prevent foaming.
Danish: Vær sikker på at natriumchloridopløsningen 9 mg/ml (0,9%) tilsættes langs hætteglassets væg for at undgå, at det skummer.
English: In the 1-day IV fosaprepitant setting, simulated median AUC0-24hr of aprepitant with median peak plasma concentration (Cmax) on Day 1 and the median concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (6 months to < 12 years old) and observed mean AUC0-24hr with median peak plasma concentration (Cmax) on Day 1 and mean concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (12 to 17 years old) are shown in Table 10.
Danish: I forbindelse med 1-dages behandling med intravenøs fosaprepitant er simuleret median AUC0-24t for aprepitant med median peak-plasmakoncentration (Cmax) på dag 1 og mediane koncentrationer i slutningen af dag 1, dag 2 og dag 3 hos pædiatriske patienter (i alderen 6 måneder til < 12 år) og observeret gennemsnitlig AUC0-24t med median peak-plasmakoncentration (Cmax) på dag 1 og gennemsnitlige koncentrationer i slutningen af dag 1, dag 2 og dag 3 hos pædiatriske patienter (i alderen 12 til 17 år) vist i tabel 10.
English: The most common adverse reactions reported at a greater incidence in paediatric patients treated with the aprepitant regimen than with the control regimen while receiving emetogenic cancer chemotherapy were hiccups (3.3 % versus 0.0 %) and flushing (1.1 % versus 0.0 %).
Danish: De hyppigste bivirkninger, der blev rapporteret med en højere frekvens hos pædiatriske patienter i aprepitantbehandling end hos kontrolregimet, mens de fik emetogen cancerkemoterapi, var: hikke (3,3% versus 0,0%) og rødme (1,1% versus 0,0%).
English: Maximum dose 115 mg
Danish: Maksimal dosis 115 mg
English: Paediatric patients 6 months to less than 2 years and not less than 6 kg
Danish: Pædiatriske patienter i alderen 6 måneder til under 2 år og som vejer mindst 6 kg
English: 6 - < 12 years old
Danish: 6 - < 12 år
English: Prepare an infusion bag filled with 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection (for example, by removing 105 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection from a 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection infusion bag).
Danish: Tilbered en infusionspose med 145 ml natriumchloridopløsning 9 mg/ml (0,9%) til injektion (fx ved at fjerne 105 ml natriumchloridopløsning 9 mg/ml (0,9%) til injektion fra en 250 ml infusionspose med natriumchloridopløsning 9 mg/ml (0,9%) til injektion).
English: How to use IVEMEND
Danish: Sådan skal du bruge IVEMEND
English: Fosaprepitant, a prodrug of aprepitant, when administered intravenously is rapidly converted to aprepitant.
Danish: Fosaprepitant, et aprepitant-prodrug, omdannes hurtigt til aprepitant, når det administreres intravenøst.
English: Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction), - euphoria (feeling of extreme happiness), disorientation, - bacterial infection, fungal infection, - severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating, - frequent urination, passing more urine than normal, presence of sugar or blood in urine, - chest discomfort, swelling, change in the manner of walking, - cough, mucus in back of throat, throat irritation, sneezing, sore throat, - eye discharge and itching, - ringing in the ear, - muscle spasms, muscle weakness, - excessive thirst, - slow heartbeat, heart and blood vessel disease, - lowering of white blood cells, low sodium levels in the blood, weight loss, - hardening of site of infusion.
Danish: Stevens-Johnsons syndrom/toksisk epidermal nekrolyse (sjælden, alvorlig hudreaktion) - Eufori (ekstrem lykkefølelse), desorientering - Bakterieinfektion, svampeinfektion - Svær forstoppelse, mavesår, betændelse i tyndtarm og tyktarm, sår i munden, oppustethed - Hyppig vandladning, større urinmængde end normalt, sukker i urinen - Gener i brystet, hævelser, ændringer i måden at gå på - Hoste, slim bagest i svælget, irritation i svælget, nysen, ondt i halsen - Tåreflåd, øjenkløe - Ringen for ørerne (tinnitus) - Muskelkramper, muskelsvækkelse - Udtalt tørst - Langsom hjerterytme (puls), sygdom i hjerte- eller blodkar - Fald i antal hvide blodlegemer, lavt indhold af natrium i blodet, vægttab - Hård infiltration på infusionsstedet.
English: The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table.
Danish: Frekvenserne, som blev observeret i de pædiatriske studier, var sammenlignelige eller lavere, medmindre andet er angivet i tabellen.
English: Rare side effects (may affect up to 1 in 1,000 people) are: - difficulty thinking, lack of energy, taste disturbance, - sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash,
Danish: Sjældne bivirkninger (forekommer hos 1 ud af 1.000 personer): - Koncentrationsbesvær, manglende energi, smagsforstyrrelser - Hudfølsomhed over for solen, øget svedtendens, fedtet hud, sår på huden, kløende udslæt,
English: Paediatric patients 6 months to less than 12 years and not less than 6 kg
Danish: Pædiatriske patienter i alderen 6 måneder til under 12 år og som vejer mindst 6 kg
English: Table 5: Tabulated list of adverse reactions - aprepitant
Danish: Tabel 5: Bivirkningstabel - aprepitant
English: The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Danish: Samtidig administration af hormonel kontraception Effekten af hormonel kontraception kan være nedsat under og i 28 dage efter behandling med fosaprepitant.
English: 150 mg intravenously
Danish: 150 mg intravenøst
English: Tell your doctor about any other medicines or herbal medicines you are taking, have recently taken, or might take.
Danish: Fortæl altid lægen, hvis du tager anden medicin eller har gjort det for nylig.
English: Do not throw away any medicines via wastewater or house hold waste.
Danish: Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden.
English: Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC0-24hr of dexamethasone, a CYP3A4 substrate, by 100 % on Day 1, 86 % on Day 2 and 18 % on Day 3 when dexamethasone was co-administered as a single 8 mg oral dose on Days 1, 2, and 3.
Danish: Fosaprepitant 150 mg givet som en enkelt intravenøs dosis på dag 1 øgede AUC0-24t for dexamethason, der er et CYP3A4-substrat, med 100% på dag 1, 86% på dag 2 og 18% på dag 3, når dexamethason blev givet samtidigt som en enkelt 8 mg oral dosis på dag 1, 2 og 3.
English: 245.3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant) to aprepitant, 23.9 mg of phosphoric acid and 95.3 mg of meglumine are liberated.
Danish: Efter omdannelse af 245,3 mg fosaprepitant dimeglumin (svarende til 150 mg fosaprepitant) til aprepitant, blev 23,9 mg phosphorsyre og 95,3 mg meglumin frigjort.
English: Withdraw the entire volume from the vial and transfer it into an infusion bag containing 145 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection to yield a total volume of 150 ml and final concentration of 1 mg/ml.
Danish: Træk hele indholdet op af hætteglasset og overfør det til infusionsposen med de 145 ml natriumchloridopløsning 9 mg/ml (0,9%) til injektion, så det i alt giver 150 ml og en endelig koncentration på 1 mg/ml.
English: Caution is advised during concomitant administration of fosaprepitant and active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.4).
Danish: Forsigtighed tilrådes ved samtidig administration af fosaprepitant og aktive substanser, der primært metaboliseres gennem CYP3A4, og som har et smalt terapeutisk virkningsområde såsom ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanyl og quinidin (se pkt.
English: AUC 0-24 hr. (ng*hr/mL)
Danish: AUC 0-24 t. (ng*t/ml)
English: Table 9: Pharmacokinetic parameters of aprepitant for 3-day IV fosaprepitant regimen in paediatric patients
Danish: Tabel 9: Aprepitants farmakokinetiske parametre for 3-dages intravenøst fosaprepitantregime hos pædiatriske patienter
English: Aprepitant is not excreted unchanged in urine.
Danish: Aprepitant udskilles omdannet i urinen.
English: When administered intravenously fosaprepitant is rapidly converted to aprepitant.
Danish: Efter intravenøs administration omdannes fosaprepitant hurtigt til aprepitant.
English: IVEMEND should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5).
Danish: IVEMEND bør anvendes med forsigtighed hos patienter, som er i samtidig behandling med aktive substanser, der primært metaboliseres gennem CYP3A4, og som har et smalt terapeutisk virkningsområde så som ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, sekalealkaloidderivater, fentanyl og quinidin (se pkt.
English: IVEMEND should not be administered intramuscularly or subcutaneously (see section 5.3).
Danish: IVEMEND bør ikke gives intramuskulært eller subkutant (se pkt.
English: Table 10: Pharmacokinetic parameters of aprepitant for 1-day IV fosaprepitant regimen in paediatric patients
Danish: Tabel 10: Aprepitants farmakokinetiske parametre for 1-dages intravenøst fosaprepitantregime hos pædiatriske patienter
English: In a juvenile toxicity study in rats treated with aprepitant from postnatal day 10 to day 63, earlier vaginal opening in females from 250 mg/kg b.i.d.
Danish: I et toksicitetsstudie med unge rotter, som blev behandlet med aprepitant fra dag 10 til dag 63 postnatalt, førte aprepitant til en tidligere vaginalåbning hos hunner fra 250 mg/kg to gange dagligt og til en forsinket præputial separation hos hanner fra 10 mg/kg to gange dagligt.
English: Concomitant administration of fosaprepitant with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result in several-fold increased plasma concentrations of aprepitant (see section 4.4).
Danish: Samtidig administration af fosaprepitant og aktive substanser, som hæmmer CYP3A4-aktivitet (fx ketoconazol, itraconazol, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon og proteasehæmmere) bør kun ske med forsigtighed, da kombinationen forventes at medføre mange gange forhøjede plasmakoncentrationer af aprepitant (se pkt.
English: Table 6: Tabulated list of adverse reactions - fosaprepitant
Danish: Tabel 6: Bivirkningstabel - fosaprepitant
English: Paediatric population: As part of a 3-day IV/IV/IV regimen, simulated median AUC0-24hr of aprepitant with median peak plasma concentration (Cmax) on Day 1 and the median concentrations at the end of Day 1, Day 2 and Day 3 in paediatric patients (6 months to 17 years old) are shown in Table 9.
Danish: regime er simuleret median AUC0-24t for aprepitant med median peak-plasmakoncentration (Cmax) på dag 1 og de mediane koncentrationer i slutningen af dag 1, dag 2 og dag 3 hos pædiatriske patienter (i alderen 6 måneder til 17 år) vist i tabel 9.
English: Infection and infestations candidiasis, staphylococcal infection rare
Danish: Candidiasis, stafylokokinfektion
English: Inject 5 ml sodium chloride 9 mg/ml (0.9 %) solution for injection into the vial.
Danish: Sprøjt 5 ml natriumchloridopløsning 9 mg/ml (0,9%) ind i hætteglasset.
English: 2 - < 6 years old
Danish: 2 - < 6 år
English: No dose adjustment is necessary for patients with renal impairment or for patients with end stage renal disease undergoing haemodialysis (see section 5.2).
Danish: Dosisjustering er ikke nødvendig hos patienter med nedsat nyrefunktion eller hos patienter med nyresygdom i slutstadiet, der undergår hæmodialyse (se pkt.
English: Day 4
Danish: Dag 4
English: The efficacy of a 3-day fosaprepitant regimen in paediatric patients is expected to be similar to that of the 3-day oral aprepitant regimen.
Danish: Virkningen af et 3-dages fosaprepitantregime hos pædiatriske patienter forventes at være sammenlignelig med virkningen af det 3-dages orale aprepitantregime.
English: IVEMEND 150 mg powder for solution for infusion Fosaprepitant
Danish: IVEMEND 150 mg pulver til infusionsvæske, opløsning fosaprepitant
English: No dose adjustment is necessary for patients with mild hepatic impairment.
Danish: Dosisjustering er ikke nødvendig hos patienter med let nedsat leverfunktion.